Baerveldt shunt lowers IOP

Article

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

An investigation, led by Dr Eamon Sharkawi, Hôpital Ophtalmique Jules-Gonin, Université de Lausanne, Switzerland, including 31 eyes with uncontrolled IOP. Each patient underwent anterior segment proton beam radiotherapy (PBRT) and Baerveldt shunt implantation.

Postoperative assessments were conducted on day 1, weeks 1, 3, 6, 9 and months 3, 6, 9 and 12 annually thereafter. IOP that was 21 mm Hg or less was defined as a surgical success, as well as 20% reduction from baseline.

Mean preoperative IOP was recorded at 3.10 mm Hg and mean IOP at the last visit was 15.0 mm Hg. The surgical success rate was 86% after using glaucoma medications. Of the eyes studied, four had minor postoperative complications but there were no local tumour recurrences, systemic metastases or no enucleations caused by ocular hypertension.

The abstract can be found in the British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.